

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/288100 A1

(43) International Publication Date
19 January 2023 (19.01.2023)

(51) International Patent Classification:

A61K 9/127 (2006.01) *A61K 47/6911* (2006.01)
A61K 9/10 (2006.01) *A61K 31/00* (2006.01)
A61K 31/015 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2022/037371

(22) International Filing Date:

15 July 2022 (15.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/222,887 16 July 2021 (16.07.2021) US

(71) Applicant: **CELATOR PHARMACEUTICALS, INC.**

[US/US]; 3170 Porter Drive, Palo Alto, California 94304 (US).

(72) Inventors: **TARDI, Paul**; 16348 60th Avenue, Surrey,

British Columbia V3S 1S4 (CA). **WAN, Leon**; 4150 West 15th Avenue, Vancouver, British Columbia V6R 3A5 (CA). **GARG, Shyam Madhusudan**; 8199 No. 1 Road, Richmond, British Columbia V7C 1T8 (CA). **GAO, Jun**; 607 Langside Avenue, Coquitlam, British Columbia V3J 2Y7 (CA). **LEGROS, Philippe**; 1303-2200 Douglas Road, Burnaby, British Columbia V5C 0G8 (CA).

(74) Agent: **ELLINGER, Martin** et al.; Morrison & Foerster

LLP, 12531 High Bluff Drive, Suite 100, San Diego, California 92130-2040 (US).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: LIPOSOMAL FORMULATIONS OF BCL INHIBITORS

(57) Abstract: Provided herein are liposomes comprising B-cell lymphoma (Bel) protein inhibitors, compositions comprising such liposomes, and methods using such formulations for treating hyperproliferative disorders.

WO 2023/288100 A1